Belimumab and Malignancy

In this article, we will discuss Belimumab and Malignancy. So, let’s get started.

Belimumab and Malignancy

The impact of treatment with Belimumab on the development of malignancies is not known. In the controlled clinical trials, malignancies (including non-melanoma skin cancers) were reported in 0.4% of patients receiving Belimumab and 0.4% of patients receiving placebo. In the controlled clinical trials, malignancies, excluding non-melanoma skin cancers, were observed in 0.2% (3/1458) and 0.3% (2/675) of patients receiving BENLYSTA and placebo, respectively. As with other immunomodulating agents, the mechanism of action of Belimumab could increase the risk for the development of malignancies.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.